What Is Depo-Provera?
Depo-Provera is an injectable form of birth control containing medroxyprogesterone acetate (a progestin).
It is commonly administered as an injection every three months to prevent pregnancy.
Depo-Provera lawsuits generally involve allegations that long-term use may be associated with an increased risk
of meningioma (typically a noncancerous tumor that develops in the membranes surrounding the brain and spinal cord),
and that users were not adequately warned about this risk.
Background:
Regulatory agencies have reviewed evidence regarding high-dose medroxyprogesterone acetate and meningioma risk.
In September 2024, the European Medicines Agency’s PRAC reported data showing an increased risk of meningioma in
people taking high doses of medroxyprogesterone acetate for several years and recommended stopping treatment if
meningioma is diagnosed.
In the United States, the FDA-approved labeling for Depo-Provera CI includes warnings advising providers to monitor
for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed.
About Depo-Provera–Related Claims
Depo-Provera lawsuits typically allege that manufacturers failed to provide adequate warnings about the potential
risk of meningioma with prolonged use, and that earlier warnings could have changed patient decision-making or
monitoring. Claims commonly raise issues such as:
Important: We are not a law firm and do not provide legal advice. We help individuals understand
the general claims process, organize intake information, and (if requested) connect them with independent attorneys
for legal guidance.
The following are common legal allegations discussed in Depo-Provera–related litigation and are provided for general informational purposes only.
Failure to Warn
Negligence
Product Liability
Potential Health Concerns Alleged in Depo-Provera Claims
Depo-Provera claims commonly focus on meningioma risk with long-term use of medroxyprogesterone acetate. Updated labeling recommends monitoring for signs and symptoms of meningioma and discontinuing Depo-Provera CI if a meningioma is diagnosed. :contentReference[oaicite:6]{index=6}
Depo-Provera Litigation Update
-
FDA Label Includes Meningioma Warning: The FDA-approved Depo-Provera CI labeling includes guidance to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed.
-
European Safety Review (EMA PRAC): The EMA’s PRAC reported evidence of increased meningioma risk with high-dose medroxyprogesterone acetate used for several years, and recommends stopping treatment if meningioma is diagnosed.
-
Federal MDL Centralization: Depo-Provera meningioma cases have been centralized in the U.S. District Court for the Northern District of Florida for coordinated discovery and pretrial proceedings.
-
Trial Scheduling: Reporting indicates the first trial in the federal Depo-Provera MDL has been scheduled for December 2026.
Our Services
Claims We Assist With
